Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
Partnerships 12
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Licensing Agreements 13
Basilea Pharma Enters into Licensing Agreement with ArQule 13
Roivant Sciences Enters into Licensing Agreement with ArQule 14
Equity Offering 15
ArQule Raises USD70 Million in Public Offering of Shares 15
ArQule to Raise Funds in Secondary Offering of Shares 17
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18
ArQule to Raise Up to USD30 Million in Issue of Shares 19
ArQule Raises USD15.3 Million in Private Placement of Shares 20
ArQule Completes Public Offering Of Common Stock For US$60 Million 21
ArQule Inc – Key Competitors 23
ArQule Inc – Key Employees 24
ArQule Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Oct 31, 2018: ArQule reports third quarter 2018 financial results 26
Aug 01, 2018: ArQule Reports Second Quarter 2018 Financial Results 28
May 07, 2018: ArQule Reports First Quarter 2018 Financial Results 30
Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 32
Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 34
May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 35
Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 36
Corporate Communications 38
May 24, 2018: ArQule Announces Two Key Appointments 38
Product News 39
06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 39
06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 40
05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 41
03/15/2018: ArQule to Present Data on Derazantinib 42
Product Approvals 43
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 43
Clinical Trials 44
Mar 15, 2018: ArQule to Provide Update on ARQ 751 44
Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 45
Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 46
Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 47
May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 49
May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 50
Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Basilea Pharma Enters into Licensing Agreement with ArQule 13
Roivant Sciences Enters into Licensing Agreement with ArQule 14
ArQule Raises USD70 Million in Public Offering of Shares 15
ArQule to Raise Funds in Secondary Offering of Shares 17
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18
ArQule to Raise Up to USD30 Million in Issue of Shares 19
ArQule Raises USD15.3 Million in Private Placement of Shares 20
ArQule Completes Public Offering Of Common Stock For US$60 Million 21
ArQule Inc, Key Competitors 23
ArQule Inc, Key Employees 24
List of Figures
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9